I thought I'd return to Bluelight with a juicy little tidbit of as-of-yet unpublished research. Michael Quick, whose lab at USC studies neurotransmitter transporters, recently came to my school to give a talk. He presented some of his work on the serotonin transporter (SERT), including how it is modulated by MDMA as well as the protein syntaxin 1A, a component of the synaptic vesicle release machinery (most of it has been published in this article: Quick MW, 2003. Regulating the conducting states of a mammalian serotonin transporter. Neuron 40(3):537-49.). After the talk, I asked him what the implications of his findings were for the two major postulated mechanisms of MDMA action: namely, reverse transport of serotonin and stimulation of vesicular release. Excited by all the work on amphetamine-induced reverse transport of dopamine that has been published recently, his lab has investigated whether similar things were going on with the SERT and MDMA-induced serotonin efflux. Surprisingly, they found nothing. The implication of this is that MDMA must induce serotonin efflux by somehow stimulating vesicular release of serotonin. In its native environment, the SERT seems to be closely associated with or bound to syntaxin 1A. This raises the possibility that MDMA directly stimulates the vesicular release machinery by inducing a cascade of protein conformational changes from SERT to syntaxin to SNAREs.
Perhaps a FRET-based assay comparing syntaxin conformational change induced by serotonin and MDMA, and looking for a FRET effect that is selectively induced by MDMA but not sertonin, could elucidate whether this is the mechanism.
Perhaps a FRET-based assay comparing syntaxin conformational change induced by serotonin and MDMA, and looking for a FRET effect that is selectively induced by MDMA but not sertonin, could elucidate whether this is the mechanism.
